Radio and PodcastRadio and PodcastLive Radio & Podcasts
109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results artwork
Science & Medicine

109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results

Breaking Biotech by Matthew Lepoire

Feb 22, 202200:33:42Science & Medicine

Karyopharm is an oncology company that is commercializing XPOVIO (Selinexor) in Multiple Myeloma and DLBCL. Selinexor blocks nuclear export thereby hindering the ability of cancer cells to block tumor suppressor protein...

About This Episode

109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results is an episode from Breaking Biotech by Matthew Lepoire. Karyopharm is an oncology company that is commercializing XPOVIO (Selinexor) in Multiple Myel...

Podcast

This episode belongs to Breaking Biotech.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published Feb 22, 2022, 00:33:42 long, audio available.

Related Episodes

Continue listening to more episodes from Breaking Biotech.